US Archives - Page 132 of 201 - European Medical Journal

Success of Platelet Ratios to Predict Biliary Sepsis Severity

In the clinical landscape of biliary tract infections, accurately predicting which patients are at risk of severe bloodstream infections (BSIs) can be lifesaving.

Unexpected Cellular Activity Found in SSc-Linked Calcinosis

In patients with systemic sclerosis (SSc), the presence of calcinosis cutis, abnormal calcium deposits in the skin, may signal a deeper issue tied to osteoclastogenesis, the formation of bone-resorbing cells, according to a new study.

Oncolytic Viruses as Emerging Immunotherapy for Nonmelanoma Skin Cancers

Oncolytic viral therapy may offer new hope for patients with nonmelanoma skin cancers and cutaneous lymphomas, according to a new systematic review of published and ongoing research.

New Global Framework Targets Superbugs in Hospitals

Next-generation sequencing (NGS) for antimicrobial resistance (AMR) could revolutionize hospital infection control, according to a newly proposed global framework from a team of international infection prevention experts.

Excess Visceral Fat Drives Cardiovascular Risk in HIV

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even in individuals…

AMJ Dermatology 2 [Supplement 2] 2025

A new study shows how gene expression profiling improves risk prediction for high-risk cutaneous squamous cell carcinoma, helping…

Optimizing Metastatic Risk Prediction in cSCC

A new study shows how gene expression profiling improves risk prediction for high-risk cutaneous squamous cell carcinoma, helping…

IFT Study Shares Fast-Acting Therapy for Acute Trigeminal Neuralgia: AAN 2025

Intravenous fosphenytoin (fPHT) demonstrated rapid and significant pain relief for patients experiencing acute exacerbations of trigeminal neuralgia (TN), according to late-breaking results from the IFT Study presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego.

Ide-Cel Shows 73% Response in Complex Multiple Myeloma Cases

In the treatment of relapsed/refractory multiple myeloma, CAR T-cell therapy using idecabtagene vicleucel (ide-cel) has demonstrated encouraging results in a large real-world U.S. patient cohort, according to new data from the CIBMTR registry.

AMJ Microbiology & Infectious Diseases 3 [Supplement 1] 2025

This poster was presented at the Conference on Retroviruses and Opportunistic Infections (CROI), held in San Francisco, California, USA…